Pushkal Garg - 12 Feb 2026 Form 4 Insider Report for ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Signature
By: Brett Budzinski, Attorney-in-Fact For: Pushkal Garg
Issuer symbol
ALNY
Transactions as of
12 Feb 2026
Net transactions value
-$695,201
Form type
4
Filing time
17 Feb 2026, 19:28:48 UTC
Previous filing
14 Jan 2026
Next filing
02 Mar 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Garg Pushkal EVP Chief R&D 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE By: Brett Budzinski, Attorney-in-Fact For: Pushkal Garg 17 Feb 2026 0001829252

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALNY Common Stock Award $0 +4,579 +20% $0.000000 27,090 12 Feb 2026 Direct F1
transaction ALNY Common Stock Sale $695,201 -2,242 -8.3% $310.08 24,848 13 Feb 2026 Direct F2, F3
holding ALNY Common Stock 431 12 Feb 2026 by Managed Account F4
holding ALNY Common Stock 250 12 Feb 2026 by Trust F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 27, 2023, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of forty (40) percent of the shares subject to the PSU based on the issuer publicly reporting the achievement of non-GAAP operating income for fiscal year 2025 on February 12, 2026, as determined by the People, Culture and Compensation Committee of the Issuer Board of Directors.
F2 Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations.
F3 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $302.55 to $314.60. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4 Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.
F5 Represents shares held in trust, of which the Reporting Persons spouse is co-trustee. The Reporting Person disclaims beneficial ownership of these shares, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.